US President Trump signs new pricing agreement with 9 pharmaceutical companies
A new pricing agreement has been reached with nine international pharmaceutical and biotechnology firms aimed at reducing the cost of healthcare in America.
US President Donald Trump announced that a new price agreement has been reached with nine pharmaceutical companies, including firms such as Astellas, BeOne Medicines, CSL, and Teva, to make healthcare more affordable for Americans.
Agreement in the Oval Office
US President Donald Trump announced the new drug pricing agreement at an event held in the Oval Office with the participation of company executives.
It was stated that these companies will provide medications to states' Medicaid programs at the most favorable prices.
Drug Costs and Discounts
Trump stated that the agreement constitutes a major discount that will significantly reduce the cost of medical care.
It is known that patients in the US pay approximately three times the prices applied in other developed countries for prescription drugs.
International Pricing Model
The administration continues to maintain pressure on pharmaceutical manufacturers to bring US prices closer to levels in other countries.
The new agreements serve as a continuation of similar understandings previously made with giant companies such as Pfizer, Eli Lilly, and Amgen.
Tariffs and Direct Sales
Companies agreed to lower the prices of certain drugs for federal health programs in exchange for tariff reductions provided.
Within the scope of the agreement, it was also decided that certain drugs would be sold directly to patients through a Trump-branded website.